SAMUEL AMOAKO: Open Payments
NPI 1245579879 · COLTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,940 in 106 payments from 12 companies in 2025. Trend: 2023 $125 · 2024 $1,027 · 2025 $1,940
Food & beverage: $1,940
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $468 |
| Teva Pharmaceuticals USA, Inc. | 18 | $341 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $301 |
| ABBVIE INC. | 10 | $190 |
| E.R. Squibb & Sons, L.L.C. | 16 | $184 |
| Neurocrine BioSciences, Inc. | 8 | $150 |
| Alkermes, Inc. | 5 | $117 |
| Vanda Pharmaceuticals Inc. | 2 | $66 |
| Janssen Pharmaceuticals, Inc | 3 | $51 |
| Bausch Health US, LLC | 2 | $29 |
Products named: REXULTI, CAPLYTA, AUSTEDO XR, VRAYLAR, INGREZZA, COBENFY, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
